Australia - engleză - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - clevidipine, quantity: 25 mg - injection, emulsion - excipient ingredients: water for injections; glycerol; soya oil; egg lecithin; sodium hydroxide; oleic acid; disodium edetate - cleviprex is indicated for the short term treatment of hypertension when oral therapy is not feasible or desirable.

Bangladesh - engleză - DGDA (Directorate General of Drug Administration)

kumudini pharma ltd. - betacarotene + vitamin c + vitamin e - tablet - 6 mg + 200 mg + 50 mg

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

carnegie medical (3m) incorp. - methenamine hippurate - tablets - 250 milligram

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

rowex ltd - escitalopram oxalate - orodispersible tablet - 5 milligram - selective serotonin reuptake inhibitors

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

rowex ltd - escitalopram oxalate - orodispersible tablet - 10 milligram - selective serotonin reuptake inhibitors

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

rowex ltd - escitalopram oxalate - orodispersible tablet - 20 milligram - selective serotonin reuptake inhibitors

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

rowex ltd - escitalopram oxalate - orodispersible tablet - 15 milligram - selective serotonin reuptake inhibitors

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

the medicines company - clevidipine (unii: 19o2gp3b7q) (clevidipine - unii:19o2gp3b7q) - clevidipine 0.5 mg in 1 ml - cleviprex is indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. cleviprex is contraindicated in patients with allergies to soybeans, soy products, eggs, or egg products. cleviprex is contraindicated in patients with defective lipid metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia. cleviprex is contraindicated in patients with severe aortic stenosis because afterload reduction can be expected to reduce myocardial oxygen delivery. pregnancy category c there are no adequate and well-controlled studies of cleviprex use in pregnant women. in animal studies, clevidipine caused increases in maternal and fetal mortality and length of gestation. cleviprex should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. there was decreased fetal survival when pregnant rats and rabbits were treated with clevidipine during organogenesis at doses 0.7 times (on

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

fresenius kabi austria gmbh - clevidipine (unii: 19o2gp3b7q) (clevidipine - unii:19o2gp3b7q) - clevidipine 0.5 mg in 1 ml - cleviprex is indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. cleviprex is contraindicated in patients with allergies to soybeans, soy products, eggs, or egg products. cleviprex is contraindicated in patients with defective lipid metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia. cleviprex is contraindicated in patients with severe aortic stenosis because afterload reduction can be expected to reduce myocardial oxygen delivery. pregnancy category c there are no adequate and well-controlled studies of cleviprex use in pregnant women. in animal studies, clevidipine caused increases in maternal and fetal mortality and length of gestation. cleviprex should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. there was decreased fetal survival when pregnant rats and rabbits were treated with clevidipine during organogenesis at doses 0.7 t

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

chiesi usa, inc. - clevidipine (unii: 19o2gp3b7q) (clevidipine - unii:19o2gp3b7q) - clevidipine 0.5 mg in 1 ml - cleviprex is indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. cleviprex is contraindicated in patients with allergies to soybeans, soy products, eggs, or egg products. cleviprex is contraindicated in patients with defective lipid metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia. cleviprex is contraindicated in patients with severe aortic stenosis because afterload reduction can be expected to reduce myocardial oxygen delivery. risk summary the available data based on post-marketing reports with cleviprex use in pregnant women are not sufficient to inform a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. there are risks to the mother and fetus associated with poorly controlled hypertension in pregnancy (see clinical considerations ). in animal studies, clevidipine was associated with increased incidences of intrauterine deaths, slightly red